Sickie for life: Autoimmune edition
Long story short, I’ve been sick for a while.
Doctors finally figured out some missing pieces!
Turns out I’m not just an anxious female (ok well I am that, too), but instead my body’s been trying to murk itself.
I was diagnosed with Mixed Connective Tissue Disease, an autoimmune disease that combines symptoms of SLE, rheumatoid arthritis, polymyositis, and scleroderma. I was also found to have a very rare t-cell cutaneous lymphoma. Thankfully, in its current form is most likely non-aggressive. I’ll be seeing specialists every 3-6 months for the rest of my life to ensure it doesn’t become aggressive :)
Don’t let yourself be gaslit into thinking nothings wrong. Trust your body!!!
#chronicdisease #mixedconnectivetissuedisease #mctd #lymphoma #autoimmune
Mixed Connective Tissue Disease (MCTD) is a complex autoimmune disorder that presents with overlapping symptoms of systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, and scleroderma. This rare condition can cause various systemic issues, including skin manifestations such as malar rash, vascular complications, muscle weakness, and joint pain. Patients with MCTD often experience diagnostic challenges due to the wide array of symptoms that overlap other autoimmune diseases. Blood tests such as ANA (antinuclear antibody), beta-2 glycoprotein antibody, cardiolipin antibody, and complement levels (C3, C4) are essential in confirming diagnosis and differentiating from other conditions. Frequent monitoring through blood work, imaging like MRIs, X-rays, and biopsies—especially skin biopsies—helps track disease progression and assess treatment efficacy. In rare cases, as illustrated by this patient's journey, individuals with MCTD may develop additional complications like CD30+ T-cell cutaneous lymphoma. This form of lymphoma affects the skin and, although non-aggressive initially, requires careful surveillance every 3-6 months because of potential progression to aggressive lymphoma. Treatment plans may include immune modulators, antibody infusions, and low-dose chemotherapy aimed at controlling autoimmune activity and preventing lymphoma escalation. Key symptoms such as unexplained bruising, ulcerative mouth and nose ulcers, spontaneous skin bumps, and damaged nail beds due to hemorrhaging capillaries highlight the systemic vascular involvement and underscore the importance of not ignoring early signs. Patients should advocate for themselves and seek specialized care, including consultations at advanced centers where comprehensive testing can guide diagnosis. Awareness and education about chronic autoimmune diseases like MCTD paired with rare lymphomas are crucial for early detection and management. Self-trust plays a critical role; dismissing symptoms or being gaslit by medical professionals can delay vital treatment. Support networks and chronic disease forums provide patient-centered insights and emotional support. To sum up, managing a rare autoimmune disease with complex presentations alongside a rare lymphoma requires collaboration between patients and multidisciplinary healthcare teams. Advances in diagnostics and targeted therapies offer hope for improved quality of life and long-term disease control.
